Clinical Trial

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis. The aim of this study is to evaluate the safety and efficacy of ADSTEM Inj. against Placebo in the treatment of atopic dermatitis in patients with moderate to severe acute and chronic atopic.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-10-22; most recent amendment 2026-06-17.
Status change: Recruiting → Active, Not Recruiting 2023-02-14
Trial Details
NCT Number NCT04137562
Lead Sponsor EHL Bio Co., Ltd.
Conditions Atopic Dermatitis
Enrollment 118 participants
Start Date 2019-12-11
Primary Completion 2023-01-26 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22